Ruxolitinib (Jakafi®) in the Management of Myelofibrosis Patients

Written By: Todd Murphree, PharmD Clearview Cancer Institute
Download Here

Description of PQI: Ruxolitinib is a selective Jak2 inhibitor used for the treatment of myelofibrosis (MF). This PQI will review the close monitoring of platelets required to ensure appropriate dose and avoid severe thrombocytopenia due to the therapy.

Background: Ruxolitinib is FDA approved for the treatment of intermediate or high-risk patients with MF. This includes patients with primary MF, post polycythemia vera MF, and post-essential thrombocytopenia MF.

PQI Process: Pharmacy management of patients’ labs to ensure correct dosing of ruxolitinib can contribute to increased efficacy and decreased toxicity of the therapy. When receiving a new prescription for ruxolitinib:

  • Review dosing
    • Dosing is based on baseline platelet count and platelet counts must be monitored throughout therapy
Baseline Platelet CountRuxolitinib Dose
>200 x 109 cells/L20 mg BID
100 to 200 x 109 cells/L15 mg BID
50 to 99 x 109 cells/L5 mg BID


  • Check for drug-drug interactions
  • Lab Monitoring
    • CBC/CMP – baseline, every 2 to 4 weeks until dose is stabilized, then as clinically indicated
    • Lipid panel – Baseline and 8 to 12 weeks after initiation
  • Ensure the patient has follow up labs scheduled appropriately (see lab monitoring section)
    • Add reminders in pharmacy management software or EMR for follow-up on patient’s labs every 2-4 weeks until dose is stabilized (usually within 8 weeks)
  • Refills will be filled only after:
    • CBC has been checked
    • Platelet count has been evaluated for appropriateness of dose

Dose Modifications:

  • Do not adjust dose within the first 4 weeks, and no more than every 2 weeks thereafter
    • Dose may be increased by 5 mg BID increments to a max dose of 25 mg BID if:
      • Failure to achieve a reduction from baseline spleen length of 50% or a 35% reduction in spleen volume as measured by CT or MRI
      • Platelet count more than 125 x 109 cells/L at treatment week 4 and platelet counts never less than 100 x 109 cells/L
      • ANC more than 0.75 x 109 cells/L
    •  Discontinue ruxolitinib if spleen size reduction or symptom improvements not observed after 6 months of therapy
    • When discontinuing therapy for any reason other than thrombocytopenia, consider gradually tapering dose by 5 mg twice daily each week
  • Evaluate platelet count and may recommend the following dose adjustments to provider:

Baseline Platelet Count of 100 x 10(9) cells/L or Higher: 1

Current Platelet CountDose Adjustment
125 x 109 cells/L or higherNo dose adjustment
100 to 124 x 109 cells/LIf starting dose was 20 mg BID, decrease dose by 5 mg BID

If starting dose was 15 mg BID or less, no adjustment needed

75 to 99 x 109 cells/LDecrease dose to 10 mg BID

If starting dose was 10 mg BID or less, no adjustment needed

50 to 74 x 109 cells/LDecrease to 5 mg BID

If starting dose was 5 mg BID, no adjustment needed

<50 x 109 cells/LHold. May restart when platelets >50 x 109 cells/L

Baseline Platelet Count of 50 to 99 x 109 cells/L: 1

Current Platelet CountDose Adjustment
25 to 35 x 109 cells/L and platelet decline during prior 4 weeks is less than 20%Decrease total daily dose by 5 mg.

For patients on 5mg once daily prior to decline, continue same dose

25 to 35 x 109 and platelet decline during prior 4 weeks is 20% or higherDecrease dose to 5mg BID

If dose is 5 mg BID, decrease to 5 mg once daily

If dose is 5 mg once daily, continue same dose

<25 x 109Hold therapy

May restart when platelets >35 x 109 cells/L starting with 5 mg BID less than previous dose


Patient Centered Activities:

  • Provide Oral Chemotherapy Education (OCE) sheet
  • Stress importance of adherence
    • The only way to achieve the proper patient-specific dose is if the patient is adherent
    • Schedule follow-up calls
  • Provide education:
  • Laboratory monitoring
  • Possibility of dose adjustments based on labs
  • Monitoring Skin:
    • Important to note all skin lesions
      • Examine skin at baseline
      • Make note of any new lesions that arise while on therapy


  1. Jakafi® (ruxolitinib) Package Insert.
Important notice: NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.

Joshua has blogged 260 posts

View all PQI